Deslorelin
Deslorelin acetate, Des-Gly10-D-Trp6-LHRH ethylamide
Deslorelin is a synthetic nonapeptide GnRH agonist that occupies an unusual position: it was studied in humans for central precocious puberty in the 1980s and 1990s at the United States National Institutes of Health, but was never brought to human registration. Today it is licensed and used only in veterinary medicine, principally as an implant for reversible chemical castration in dogs and for oestrus control in other species.
Mechanism
Deslorelin replaces glycine at position 6 of native GnRH with D-tryptophan and substitutes an ethylamide for the C-terminal glycinamide, the same design logic used across the agonist class. The bulky D-tryptophan blocks the endopeptidase cleavage that inactivates native GnRH within minutes, while the ethylamide resists carboxypeptidase attack and increases receptor affinity. The resulting analogue is far more potent and longer-acting than the parent hormone. It is structurally very close to triptorelin, which retains the full decapeptide with a glycinamide terminus.
The pharmacodynamics are those of any GnRH agonist delivered continuously. Sustained receptor occupancy first triggers a flare of LH and FSH release, transiently raising testosterone or oestradiol, and then causes GnRH receptor downregulation and gonadotroph desensitisation, collapsing gonadotrophin output and driving sex steroids to castrate concentrations. In the veterinary chemical castration application this is the entire therapeutic point: a single implant produces reversible infertility and testosterone suppression in male dogs for a minimum of six or twelve months depending on the formulation, after which function returns as the implant is exhausted. Notably, the flare phase in veterinary use means fertility may transiently increase in the first weeks after implantation before suppression takes hold, a practical consideration that mirrors the flare problem in human oncology.
What the research shows
The substantive human evidence comes from a National Institutes of Health programme in central precocious puberty. A dose-ranging study established that deslorelin suppressed gonadotrophin and sex steroid secretion in a dose-dependent manner, identifying the exposure needed to achieve consistent pubertal arrest, useful pharmacological work that clarified how much agonist is required to reliably desensitise the paediatric pituitary. A companion study reported adult height in children with precocious puberty after long-term deslorelin treatment, finding that treated children achieved adult heights greater than their pre-treatment predicted heights. Because these were single-arm studies without randomised controls, and because predicted adult height is an imprecise instrument in children with advanced bone age, the magnitude of benefit should be treated as approximate rather than established. Deslorelin was also used as the GnRH agonist component in a study of familial male-limited precocious puberty, added after central puberty onset supervened on spironolactone and testolactone treatment, a small, specialised application in a rare disorder.
What did not happen is as informative as what did. Deslorelin was never taken through human registration, and the indications it was studied for are now served by licensed leuprorelin, triptorelin and histrelin preparations with far larger evidence bases. Its commercial life instead went to veterinary medicine, where deslorelin implants are authorised as veterinary medicinal products in the European Union, the United Kingdom, Australia and New Zealand among other markets, for inducing temporary infertility in healthy male dogs and for reproductive control in other species. That veterinary evidence is substantial and the product is well characterised in dogs, but it says nothing about human safety or efficacy that the human studies do not already say better.
Evidence assessment
Limited evidence
DOWNGRADED FROM "mixed" ON AUDIT. "Mixed" implies conflicting human results; deslorelin's human evidence is not conflicting, it is simply thin. All three surviving human citations are small, single-centre, uncontrolled studies from a single National Institutes of Health programme between 1991 and 1999. None was randomised, none has been independently replicated, and no regulator anywhere has ever approved deslorelin for human use. Small, dated, uncontrolled and unreplicated human data with no approved labelling is the definition of limited. Its veterinary licensure, however robust, is not human evidence and does not raise the tier.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Effect of deslorelin dose in the treatment of central precocious puberty Preclinical only
Deslorelin suppressed gonadotrophin and sex steroid secretion in a dose-dependent manner, establishing the exposure required for consistent pubertal arrest. Small, single-centre, no randomised control group.
Adult height in precocious puberty after long-term treatment with deslorelin Preclinical only
Adult heights achieved exceeded pre-treatment predicted heights. Because there was no randomised control arm and predicted adult height is imprecise in children with advanced bone age, the magnitude of benefit is approximate rather than established.
Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset Preclinical only
Deslorelin was added when central puberty supervened on peripheral precocious puberty, providing gonadotrophin suppression in this rare disorder. Very small specialised cohort with no control group.
Safety
Human safety data for deslorelin are limited to the small historical paediatric studies and should not be assumed comparable in completeness to the licensed GnRH agonists. On mechanistic grounds the expected profile is the class profile: an initial flare with transient worsening of pubertal signs or, in adults, a transient rise in sex steroids; then hot flushes, reduced libido, fatigue, mood change and, with prolonged exposure, loss of bone mineral density. In men the flare would carry the same theoretical risk of transiently worsening hormone-sensitive disease that necessitates antiandrogen cover with licensed agonists. Because deslorelin has no human marketing authorisation anywhere, material sold for human use is by definition unlicensed and outside pharmaceutical quality oversight. Purity, identity and sterility are not assured, which is a meaningful hazard independent of the molecule's own pharmacology. Veterinary implant products are formulated and dose-scaled for animals and are not interchangeable with any human preparation.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA human marketing authorisation. Deslorelin is authorised in the United Kingdom and European Union only as a veterinary medicinal product, principally as a subcutaneous implant for inducing temporary infertility in male dogs, available on veterinary prescription. |
| United States | No FDA approval for human use. Deslorelin has never held a human marketing authorisation in the United States. Veterinary products containing deslorelin exist under separate veterinary regulatory pathways. |
| WADA (sport) | Prohibited in male athletes at all times under section S2 of the WADA Prohibited List, which explicitly names deslorelin among gonadotrophin-releasing hormone agonist analogues. Not prohibited in female athletes. |
Questions
No. Deslorelin has never received human marketing authorisation from the FDA, the MHRA or the EMA. It was studied in humans for central precocious puberty in small trials three decades ago but was never taken to registration. Its only current licences are veterinary.
Limited, and it is worth saying so plainly. Three small, single-centre, uncontrolled studies from one research programme in the 1990s, none randomised and none independently replicated. They show that deslorelin suppresses the reproductive axis, which is unsurprising for a GnRH agonist, but they do not constitute the kind of evidence base a licensed medicine carries.
The mechanism is conserved (GnRH receptor biology is similar across mammals) and the small historical human studies did show pubertal suppression. But veterinary licensure tells you the product is safe and effective in dogs at veterinary doses and formulations. It is not a substitute for human trial data, human dosing work, or pharmaceutical quality oversight for human use.
They are structurally close relatives. Triptorelin retains the full ten-residue backbone with a glycinamide C-terminus, while deslorelin is a nine-residue analogue ending in an ethylamide; both carry a D-tryptophan at position 6. Their pharmacology is similar, but triptorelin was developed through human registration and has a large licensed evidence base, whereas deslorelin was not.
Because deslorelin is an agonist, not a blocker. Continuous stimulation first provokes a surge of LH and FSH before the pituitary downregulates. In veterinary use this means a male dog may be transiently more fertile in the weeks after implantation, which is a well-recognised practical caveat and the direct animal equivalent of the tumour flare seen with agonists in human oncology.